Primary Care Patient Interest in Multi-Cancer Early Detection for Cancer Screening
-
Published:2023-11-16
Issue:11
Volume:13
Page:1613
-
ISSN:2075-4426
-
Container-title:Journal of Personalized Medicine
-
language:en
-
Short-container-title:JPM
Author:
Myers Ronald E.1, Hallman Mie H.1, Shimada Ayako2ORCID, DiCarlo Melissa1, Davis Kaitlyn3ORCID, Leach William T.3, Jackson Hattie1ORCID, Indictor Amanda1, Chambers Christopher V.3
Affiliation:
1. Division of Population Science, Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA 19107, USA 2. Division of Biostatistics, Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA 3. Department of Family and Community Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USA
Abstract
Multi-cancer early detection (MCED) tests are being developed, but little is known about patient receptivity to their use for cancer screening. The current study assessed patient interest in such testing. Our team conducted a prospective, observational study among primary care patients in a large, urban health system. They were asked to complete a telephone survey that briefly described a new blood test in development to identify multiple types of cancer, but was not currently recommended or covered by insurance. The survey included items to assess respondent background characteristics, perceptions about MCED testing, and interest in having such an MCED test. We also used multivariable analyses to identify factors associated with patient interest in test use. In 2023, we surveyed 159 (32%) of 500 identified patients. Among respondents, 125 (79%) reported a high level of interest in having an MCED test. Interest was not associated with personal background characteristics, but was positively associated with the following expectations: testing would be recommended for cancer screening, be convenient, and be effective in finding early-stage disease (OR = 11.70, 95% CI: 4.02, 34.04, p < 0.001). Research is needed to assess patient interest and actual uptake when detailed information on testing is presented in routine care.
Funder
Thomas Jefferson University’s Sidney Kimmel Cancer Center Exact Sciences Corporation, Madison, WI, USA
Subject
Medicine (miscellaneous)
Reference30 articles.
1. Lokshin, A., Bast, R.C., and Rodland, K. (2021). Circulating Cancer Biomarkers. Cancers, 13. 2. Nadauld, L.D., McDonnell, C.H., Beer, T.M., Liu, M.C., Klein, E.A., Hudnut, A., Whittington, R.A., Taylor, B., Oxnard, G.R., and Lipson, J. (2021). The PATHFINDER Study: Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test into Clinical Practice. Cancers, 13. 3. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set;Klein;Ann. Oncol.,2021 4. National Cancer Institute Division of Cancer Prevention (2023, October 24). Multi-Cancer Detection (MCD) Research, Available online: https://prevention.cancer.gov/major-programs/multi-cancer-detection-mcd-research. 5. United States Preventive Services Taskforce (2023, October 24). Recommendation: Lung Cancer: Screening. Available online: https://www.uspreventiveservicestaskforce.org/uspstf/index.php/recommendation/lung-cancer-screening#bootstrap-panel--13.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|